Star­tups raised mil­lions to in-li­cense drugs to Chi­na. Then the mod­el fell apart

Every com­pa­ny name tells a sto­ry. Lian­Bio’s is in the Chi­nese char­ac­ter on its lo­go: 聯 — which means to link, to unite, to con­nect.

Launched in 2020 by Amer­i­can in­vest­ment firm Per­cep­tive Ad­vi­sors, Lian­Bio in-li­censed ex­per­i­men­tal ther­a­pies from US and Eu­ro­pean biotechs to de­vel­op and com­mer­cial­ize in Chi­na. As it wrote in its IPO pa­pers a year lat­er, “It is our vi­sion to serve as a gate­way to Chi­na for West­ern bio­phar­ma­ceu­ti­cal com­pa­nies fo­cused on the large ad­dress­able mar­ket un­locked by” new ad­vances and re­forms.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER